FDA approves Watson's generic of pain medicine Kadian

11/10/2011 | Wall Street Journal, The

Watson Pharmaceuticals secured FDA approval for extended-release morphine sulfate, a generic version of Actavis Group's painkiller Kadian. Separately, Watson was sued by Novartis in connection with the former's FDA application to market a generic version of Exelon, the latter's drug patch for dementia.

View Full Article in:

Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA